Only a few symptomatic treatments (to control agitation) for dementia with Lewy bodies are approved today, and at present, no disease-modifying therapeutics exist for these patients. Cognition Therapeutics is conducting SHIMMER, a Phase 2 clinical trial investigating whether CT1812 has a beneficial effect in adults diagnosed with mild to moderate DLB. The company has been awarded a grant from the National Institute of Aging (part of the National Institutes of Health) to support the ongoing SHIMMER clinical trial.
DEMENTIA WITH LEWY BODIES
- Day-to-day fluctuations in alertness level
- Auditory and visual hallucinations, often of children or animals
- Resting tremors and movement disorders (shuffling gait)
- REM sleep disorder (acting out dreams while sleeping)
Cognition Therapeutics is committed to educating the public about DLB’s signs, symptoms, risk factors, and the impact of the disease on patients and caregivers. Cognition has built relationships with advocates and physician experts to learn first-hand from patients with DLB to better understand their needs. Through our Cognition Conversations podcast, we share advice and give voice to the experiences of patients and those caring for loved ones suffering from DLB.
- The results of in vitro studies in neurons suggest that σ-2 receptor modulators, such as CT1812, block the toxic effects of α-synuclein oligomers.
- It has further been demonstrated in in vitro studies in neurons that σ-2 receptor modulators such as CT1812, block the toxic effects of Aβ oligomers.
- Safety and tolerability of CT1812 has been characterized through completed and ongoing clinical trials in the company’s Alzheimer’s disease program.
- We are currently undertaking a Phase 2 study in adults who have a diagnosis of DLB.
- For more information, please visit shimmerDLBstudy.com or clinicaltrials.gov and reference NCT05225415.